Refining Early Antitumoral Drug Development

Alberto Ocaña; Sara García-Alonso; Eitan Amir; Atanasio Pandiella

doi:10.1016/j.tips.2018.09.003

Refining Early Antitumoral Drug Development

Trends Pharmacol Sci. 2018 Nov;39(11):922-925. doi: 10.1016/j.tips.2018.09.003. Epub 2018 Sep 29.

Authors

Alberto Ocaña¹, Sara García-Alonso², Eitan Amir³, Atanasio Pandiella⁴

Affiliations

¹ Translational Research Unit, Albacete University Hospital, Albacete, Spain; CIBERONC, Madrid, Spain.
² CIBERONC, Madrid, Spain; Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain; CSIC-IBSAL, Salamanca, Spain.
³ Princess Margaret Cancer Centre and the University of Toronto, Canada.
⁴ CIBERONC, Madrid, Spain; Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain; CSIC-IBSAL, Salamanca, Spain. Electronic address: atanasio@usal.es.

PMID: 30279003
DOI: 10.1016/j.tips.2018.09.003

Abstract

The failure rate of development of new drugs in oncology is high, with up to 95% of drugs tested in Phase I not reaching the market. Causes behind this high failure rate are discussed here, and solutions to increase the success in the development of antitumor drugs are suggested.

Keywords: drug development; oncology.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antineoplastic Agents* / therapeutic use
Drug Development*
Humans
Neoplasms / therapy
Organoids
Tumor Cells, Cultured

Substances

Antineoplastic Agents